Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875969 | 0.83 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2PFKFB3LOXL2 | |
| SCHEMBL24198772 | 0.82 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2PFKFB3LOXL2 | |
| SCHEMBL24198786 | 0.81 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2LOXL2RIPK1 | |
| SCHEMBL24198783 | 0.81 | AR (0.45) | RIPK1ALDH1A1LMNA | |
| SCHEMBL27144504 | 0.76 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2PFKFB3LOXL2 | |
| SCHEMBL29967026 | 0.73 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2PFKFB3LOXL2 | |
| SCHEMBL21186726 | 0.73 | ACHE (0.46) | RIPK1POLB | |
| SCHEMBL1437180 | 0.73 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2PFKFB3LOXL2 | |
| SCHEMBL12948138 | 0.72 | MLYCD (0.42) | RIPK1ALDH1A1CYP1A2 | |
| SCHEMBL13702293 | 0.72 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2RIPK1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | TAS1R3 3926/4885TAS1R1 4287/4885TAS1R2 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.